secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2022-03-07T23:59:59+00:00
Accession:  0001104659-22-030888
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead's Trodelvy meets Phase 3 endpoint in HR+/HER2- metastatic breast cancer
------------------------------------------------------------------------------

- TROPiCS-02 met primary endpoint: statistically significant PFS improvement vs physician's choice chemo in 543 patients.
- First interim OS analysis showed numerical improvement but not statistically significant; final OS readout expected in 2024.
- Safety profile consistent with prior studies; no new safety concerns observed.
- Gilead reaffirms 2022 guidance; oncology revenue goal of 1/3 by 2030 unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000110465922030888/0001104659-22-030888-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000110465922030888/tm228518d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-030888

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer